With so many patients relying on novel therapeutics for neurological disorders, the stakes are high when therapies reach the clinic. The best way to improve your chance for success is to design rigorous preclinical studies that include reproducible endpoints and robust biomarkers that predict clinical efficacy.

We hope you’ll join us as we explore this topic in a full day of engaging presentations and stimulating discussion with notable neuroscientists from biotech, pharma, and academia. You’ll learn more about the current state of biomarkers for widely studied neurological disorders, including neurodegeneration and psychiatric disease, and learn how to develop robust endpoints that can be used in clinical trials. Our symposium will conclude with a reception at our new neuroscience-focused site.

All proceeds from this symposium will be donated to Schurig Center for Brain Injury Recovery.